These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 35534000)
1. Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation. Ladbury C; Somlo G; Dagis A; Yang D; Armenian S; Song JY; Sahebi F; Spielberger R; Popplewell L; Parker P; Forman S; Snyder D; Rincon A; Liu A; Frankel P; Wong J Transplant Cell Ther; 2022 Jul; 28(7):367.e1-367.e9. PubMed ID: 35534000 [TBL] [Abstract][Full Text] [Related]
2. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Somlo G; Spielberger R; Frankel P; Karanes C; Krishnan A; Parker P; Popplewell L; Sahebi F; Kogut N; Snyder D; Liu A; Schultheiss T; Forman S; Wong JY Clin Cancer Res; 2011 Jan; 17(1):174-82. PubMed ID: 21047977 [TBL] [Abstract][Full Text] [Related]
3. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221 [TBL] [Abstract][Full Text] [Related]
4. Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m²) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma. Cailleteau A; Maingon P; Choquet S; Bourdais R; Antoni D; Lioure B; Hulin C; Batard S; Llagostera C; Guimas V; Touzeau C; Moreau P; Mahé MA; Supiot S Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):677-685. PubMed ID: 36174802 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670 [TBL] [Abstract][Full Text] [Related]
6. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747 [TBL] [Abstract][Full Text] [Related]
7. Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma. Giebel S; Sobczyk-Kruszelnicka M; Blamek S; Saduś-Wojciechowska M; Najda J; Czerw T; Mendrek W; Woźniak G; Jochymek B; Radwan M; Leszczyński W; Dolla Ł; D'Amico A; Ślosarek K; Hołowiecki J; Miszczyk L Bone Marrow Transplant; 2021 Jun; 56(6):1297-1304. PubMed ID: 33339899 [TBL] [Abstract][Full Text] [Related]
8. Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma. Ladbury C; Sanchez J; Chowdhury A; Palmer J; Liu A; Stein A; Htut M; Farol L; Cai JL; Somlo G; Rosenzweig M; Wong JC; Sahebi F Am J Clin Oncol; 2024 Jul; 47(7):325-332. PubMed ID: 38483213 [TBL] [Abstract][Full Text] [Related]
9. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892 [TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation for multiple myeloma: Long-term results. Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994 [TBL] [Abstract][Full Text] [Related]
11. Total marrow irradiation as part of autologous stem cell transplantation for Asian patients with multiple myeloma. Lin SC; Hsieh PY; Shueng PW; Tien HJ; Wang LY; Hsieh CH Biomed Res Int; 2013; 2013():321762. PubMed ID: 24089671 [TBL] [Abstract][Full Text] [Related]
12. Final outcomes of escalated melphalan 280 mg/m Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806 [TBL] [Abstract][Full Text] [Related]
13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506 [TBL] [Abstract][Full Text] [Related]
14. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375 [TBL] [Abstract][Full Text] [Related]
15. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631 [TBL] [Abstract][Full Text] [Related]
16. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study. Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830 [TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC; Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586 [TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome. Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S; Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525 [TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476 [TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]